Importer of Controlled Substances Registration: Myoderm, 29336-29337 [2015-12329]
Download as PDF
<![CDATA[
29336
Federal Register / Vol. 80, No. 98 / Thursday, May 21, 2015 / Notices
appropriate mitigation measures were
identified. The selected alternatives
were determined to be the
‘‘environmentally preferred’’ course of
action.
Dated: January 30, 2015.
Christine S. Lehnertz,
Regional Director, Pacific West Region.
[FR Doc. 2015–12376 Filed 5–20–15; 8:45 am]
BILLING CODE 4312–FF–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–940]
Certain Snowmobiles With Engines
Having Exhaust TemperatureControlled Engine Technology and
Components Thereof; Termination of
an Investigation on the Basis of
Withdrawal of the Complaint
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has determined not to
review the presiding administrative law
judge’s (‘‘ALJ’’) initial determination
(‘‘ID’’) (Order No. 11) granting the
complainant’s motion to terminate the
above-captioned investigation in its
entirety on the basis of withdrawal of
the complaint. The Commission has
terminated the investigation.
FOR FURTHER INFORMATION CONTACT:
Sidney A. Rosenzweig, Office of the
General Counsel, U.S. International
Trade Commission, 500 E Street SW.,
Washington, DC 20436, telephone (202)
708–2532. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW., Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
may also be obtained by accessing its
Internet server at https://www.usitc.gov.
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted this investigation
on December 24, 2014, based on a
complaint filed by Arctic Cat Inc. of
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
20:28 May 20, 2015
Jkt 235001
Plymouth, MN (‘‘Arctic Cat’’). 79 FR
77526 (Dec. 24, 2014). The complaint
alleged violations of section 337 of the
Tariff Act of 1930, as amended, 19
U.S.C. 1337, in the importation into the
United States, the sale for importation,
and the sale within the United States
after importation of certain
snowmobiles with engines having
exhaust temperature-controlled engine
technology and components thereof by
reason of infringement of certain claims
of three United States patents. The
Commission’s notice of investigation
named as respondents Bombardier
´
Recreational Products, Inc. of Quebec,
Canada; and BRP US Inc. of Sturtevant,
Wisconsin.
On April 23, 2015, Arctic Cat filed an
unopposed motion to terminate the
investigation in its entirety based upon
withdrawal of the complaint. On April
24, 2015, the ALJ granted the motion as
an ID (Order No. 11).
No petitions for review were filed.
The Commission has determined not to
review the ID. The Commission has
terminated the investigation.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in the
Commission’s Rules of Practice and
Procedure (19 CFR part 210).
By order of the Commission.
Issued: May 18, 2015.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2015–12301 Filed 5–20–15; 8:45 am]
BILLING CODE 7020–02–P
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on
December 11, 2014, PCAS-Nanosyn,
LLC, 3331–B Industrial Drive, Santa
Rosa, California 95403 applied to be
registered as a bulk manufacturer of the
following basic classes of controlled
substances:
Controlled substance
Oxycodone (9143) ........................
Oripavine (9330) ...........................
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
Schedule
II
II
II
II
The company is a contract
manufacturer. At the request of the
company’s customers, it manufactures
derivatives of controlled substances in
bulk form.
Drug Enforcement Administration
Dated: May 15, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[Docket No. DEA–392]
[FR Doc. 2015–12330 Filed 5–20–15; 8:45 am]
DEPARTMENT OF JUSTICE
Bulk Manufacturer of Controlled
Substances Application: PCAS–
NANOSYN, LLC
ACTION:
Notice of application.
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Registered bulk manufacturers of
the affected basic classes and applicants
therefore may file written comments or
objections to the issuance of the
proposed registration in accordance
with 21 CFR 1301.33(a) on or before July
20, 2015.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODXL, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
DATES:
BILLING CODE 4410–09–P
[Docket No. DEA–392]
Importer of Controlled Substances
Registration: Myoderm
ACTION:
Notice of registration.
Myoderm applied to be
registered as an importer of certain basic
classes of controlled substances. The
Drug Enforcement Administration
(DEA) grants Myoderm registration as an
importer of those controlled substances.
SUPPLEMENTARY INFORMATION: By notice
dated February 5, 2015, and published
in the Federal Register on February 11,
SUMMARY:
E:\FR\FM\21MYN1.SGM
21MYN1
29337
Federal Register / Vol. 80, No. 98 / Thursday, May 21, 2015 / Notices
2015, 80 FR 7633, Myoderm, 48 East
Main Street, Norristown, Pennsylvania
19401 applied to be registered as an
importer of certain basic classes of
controlled substances. No comments or
objections were submitted for this
notice.
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of
Myoderm to import the basic classes of
controlled substances is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above-named
company is granted registration as an
importer of the basic classes controlled
substances:
Controlled substance
Schedule
tkelley on DSK3SPTVN1PROD with NOTICES
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Nabilone (7379) ............................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Levomethorphan (9210) ...............
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import the
listed controlled substances in finished
dosage form for clinical trials, and
research.
The import of the above listed basic
classes of controlled substances will be
granted only for analytical testing and
clinical trials. This authorization does
not extend to the import of a finished
FDA approved or non-approved dosage
form for commercial sale.
Dated: May 15, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–12329 Filed 5–20–15; 8:45 am]
BILLING CODE 4410–09–P
VerDate Sep<11>2014
20:28 May 20, 2015
Jkt 235001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration: Mylan Pharmaceuticals,
Inc.
ACTION:
Dated: May 15, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–12327 Filed 5–20–15; 8:45 am]
BILLING CODE P
Notice of registration.
Mylan Pharmaceuticals, Inc.
applied to be registered as an importer
of certain basic classes of controlled
substances. The Drug Enforcement
Administration (DEA) grants Mylan
Pharmaceuticals, Inc. registration as an
importer of those controlled substances.
SUPPLEMENTARY INFORMATION: By notice
dated January 9, 2015, and published in
the Federal Register on January 26,
2015, 80 FR 3980, Mylan
Pharmaceuticals, Inc., 781 Chestnut
Ridge Road, Morgantown, West Virginia
26505 applied to be registered as an
importer of certain basic classes of
controlled substances. No comments or
objections were submitted for this
notice.
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of
Mylan Pharmaceuticals, Inc. to import
the basic classes of controlled
substances is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. The DEA investigated the
company’s maintenance of effective
controls against diversion by inspecting
and testing the company’s physical
security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above-named
company is granted registration as an
importer of the basic classes of
controlled substances:
SUMMARY:
Controlled substance
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Methadone (9250) ........................
Morphine (9300) ...........................
Fentanyl (9801) ............................
Schedule
II
II
II
II
II
II
II
The company plans to import the
listed controlled substances in finished
dosage form (FDF) from foreign sources
for analytical testing and clinical trials
in which the foreign FDF will be
compared to the company’s own
domestically-manufactured FDF. This
PO 00000
analysis is required to allow the
company to export domesticallymanufactured FDF to foreign markets.
Frm 00039
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration: Noramco, Inc.
ACTION:
Notice of registration.
Noramco, Inc. applied to be
registered as an importer of certain basic
classes of controlled substances. The
Drug Enforcement Administration
(DEA) grants Noramco, Inc. registration
as an importer of those controlled
substances.
SUMMARY:
By notice
dated January 9, 2015, and published in
the Federal Register on January 26,
2015, 80 FR 3980, Noramco, Inc., 500
Swedes Landing Road, Wilmington,
Delaware 19801–4417 applied to be
registered as an importer of certain basic
classes of controlled substances. No
comments or objections were submitted
for this notice. Comments and request
for hearings on applications to import
narcotic raw material are not
appropriate. 72 FR 3417 (January 25,
2007).
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of
Noramco, Inc. to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. The
DEA investigated the company’s
maintenance of effective controls
against diversion by inspecting and
testing the company’s physical security
systems, verifying the company’s
compliance with state and local laws,
and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above-named
company is granted registration as an
importer of the basic classes of
controlled substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Phenylacetone (8501) ..................
E:\FR\FM\21MYN1.SGM
21MYN1
Schedule
II
]]>Agencies
[Federal Register Volume 80, Number 98 (Thursday, May 21, 2015)]
[Notices]
[Pages 29336-29337]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-12329]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Registration: Myoderm
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: Myoderm applied to be registered as an importer of certain
basic classes of controlled substances. The Drug Enforcement
Administration (DEA) grants Myoderm registration as an importer of
those controlled substances.
SUPPLEMENTARY INFORMATION: By notice dated February 5, 2015, and
published in the Federal Register on February 11,
[[Page 29337]]
2015, 80 FR 7633, Myoderm, 48 East Main Street, Norristown,
Pennsylvania 19401 applied to be registered as an importer of certain
basic classes of controlled substances. No comments or objections were
submitted for this notice.
The DEA has considered the factors in 21 U.S.C. 823, 952(a) and
958(a) and determined that the registration of Myoderm to import the
basic classes of controlled substances is consistent with the public
interest and with United States obligations under international
treaties, conventions, or protocols in effect on May 1, 1971. The DEA
investigated the company's maintenance of effective controls against
diversion by inspecting and testing the company's physical security
systems, verifying the company's compliance with state and local laws,
and reviewing the company's background and history.
Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in
accordance with 21 CFR 1301.34, the above-named company is granted
registration as an importer of the basic classes controlled substances:
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Lisdexamfetamine (1205).................... II
Methylphenidate (1724)..................... II
Pentobarbital (2270)....................... II
Nabilone (7379)............................ II
Codeine (9050)............................. II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Hydrocodone (9193)......................... II
Levomethorphan (9210)...................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Methadone intermediate (9254).............. II
Morphine (9300)............................ II
Oxymorphone (9652)......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to import the listed controlled substances in
finished dosage form for clinical trials, and research.
The import of the above listed basic classes of controlled
substances will be granted only for analytical testing and clinical
trials. This authorization does not extend to the import of a finished
FDA approved or non-approved dosage form for commercial sale.
Dated: May 15, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-12329 Filed 5-20-15; 8:45 am]
BILLING CODE 4410-09-P
